GlassScriptPhysician profile
Cheyanne M Casas
NPI 1528047693
$1,682.66
in general payments reported to CMS, 2019-2025
21 companies · $1,150 in 2025
The $1,150 reported for 2025 was more than what 88% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $16.14 · 2024: $516 · 2025: $1,150.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,640 · Education: $26.60.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,639.92 |
| Education | $26.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $306.59 | 2024-2025 | Emgality, Mounjaro, Zepbound |
| Astrazeneca Pharmaceuticals LP | $214.25 | 2021-2025 | Farxiga, Airsupra |
| Csl Behring | $129.13 | 2025 | Hizentra |
| Teva Pharmaceuticals USA, INC. | $117.75 | 2024-2025 | Ajovy |
| Abbott Laboratories | $104.46 | 2024-2025 | Freestyle Libre 3, Octrode |
| Novo Nordisk INC | $102.70 | 2024-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $91.91 | 2025 | |
| Axsome Therapeutics, INC. | $82.19 | 2025 | Symbravo |
| Pfizer INC. | $76.65 | 2024-2025 | |
| Exact Sciences Corporation | $72.52 | 2024 | Cologuard Collection Kit |
| Lundbeck LLC | $70.53 | 2025 | Vyepti |
| Argenx US, INC. | $61.21 | 2025 | Vyvgart Hytrulo |
| Takeda Pharmaceuticals U.S.A., INC. | $59.17 | 2025 | Hyqvia |
| Sequel Med Tech, LLC | $50.14 | 2025 | Twiist |
| Boehringer Ingelheim Pharmaceuticals, INC. | $32.87 | 2024 | Jardiance |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Hologic Sales and Service, LLC | $23.76 | 2025 | Aptima |
| Tandem Diabetes Care, INC. | $20.96 | 2024 | T:Slim X2 Insulin Pump With Control-Iq |
| Dexcom, INC. | $18.19 | 2024 | Dexcom G6 Transmitter |
| Insulet Corporation | $16.77 | 2025 | Omnipod |
| Impel Pharmaceuticals LLC | $15.93 | 2025 | Trudhesa |
| Glaxosmithkline, LLC. | $14.98 | 2025 | Shingrix, Arexvy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cheyanne Casas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.